Meme Kanseri Tedavisinde Radyoterapi Teknikleri
Özet
Dünya çapında meme kanseri, kadınlarda en sık teşhis edilen kanser türü olup, kanserden ölümlerin de önde gelen nedenlerindendir. (1).Yeni teşhis edilen, metastatik olmayan meme kanseri olan kadınlar için tedavi; cerrahi, radyasyon onkolojisi ve tıbbi onkolojiyi içeren multidisipliner bir yaklaşımdan oluşur. Radyoterapi(RT), tümör kontrolünü ve yaşam kalitesini en üst düzeye çıkarırken toksisiteyi en aza indirmek ve organları korumak için çok çeşitli malignitelerde kombine modalite yaklaşımlarında cerrahi ve sistemik tedavilerle birlikte giderek daha fazla kullanılmaktadır. Çeşitli ortamlarda, RT tek tedavi olabilir, sistemik ajanlarla eş zamanlı olarak verilebilir veya tedaviden sonra mikroskobik hastalık kalma olasılığını en aza indirmek için ameliyattan önce veya sonra verilebilir. Ek olarak, hastalık tedavi edilemez olduğunda RT palyatif olarak kullanılabilir. Bu bölümde, meme kanseri tedavisinde kullanılan farklı RT modalitelerinin temel özellikleri gözden geçirilecektir.
Referanslar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249
Baker GR. Localization: conventional and CT simulation. Br J Radiol 2006; 79 Spec No 1:S36.
Madu CN, Quint DJ, Normolle DP, et al. Definition of the supraclavicular and infraclavicular nodes: implications for three-dimensional CT-based conformal radiation therapy. Radiology 2001; 221:333.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov;378(9804):1707-16. Epub 2011 Oct 19.
Fisher B, Bauer M, Margolese R, et al. Lumpectomy versus mastectomy for the treatment of invasive breast cancer: a randomized trial. N Engl J Med. 2002;347(16):1233–1241.
The START Trialists' Group, Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trials A and B of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results. Lancet Oncol. 2013;14(11):1086–1094.
Whelan TJ, Pignol J-P, Levine MN, et al. Long- term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–520.
Bartelink H, Maingon P, Poortmans P, et al. Whole breast irradiation with or without a boost for patients treated with breast- conserving surgery for early breast cancer: 20 year follow up of a randomised phase 3 trial. Lancet Oncol.
Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337(14):949–955.
Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Group 82c randomised trial. Lancet. 1999;353(9165):1641–1648.
Ragaz J, Jackson SM, Le N, Plenderleith L, Spinelli JJ, Basco VE, Wilson J, Talbot S. Adjuvant radiochemotherapy for premenopausal women with high risk breast cancer. N Engl J Med. 1997;337(14):956–962.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Le-Petit F, Anderson SJ, Ballman KV. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: ACOSOG Z1071 clinical trial. JAMA. 2013;310(14):1455–1461.
National Cancer Institute. NSABP B 51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal Radiation versus No Radiation in Patients with Pathologically Positive Axillary Nodes after Neoadjuvant Chemotherapy and Mastectomy. ClinicalTrials.gov identifier: NCT01872975.
Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008 Apr 1;26(13):2085-92.
Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000; 46:619.
Paganetti H. Changes in tumor cell response due to prolonged dose delivery times in fractionated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 63:892.
Schäfer M, Münter M, Sterzing F, et al. Measurements of characteristics of time pattern in dose delivery in step-and-shoot IMRT. Strahlenther Onkol 2005; 181:587.
Sterzing F, Münter MW, Schäfer M, et al. Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol 2005; 181:42.
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987-98.
The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–341.
The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–1107.
Agrawal RK, Aird EGA, Barrett JM, et al. The UK FAST trial: a randomised trial of radiotherapy hypofractionation for treatment of early breast cancer. Lancet Oncol. 2007;8(1):33–40
Murray Brunt A, Haviland JS, Wheatley D, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks in the adjuvant treatment of early breast cancer (FAST-Forward): 5-year efficacy and late normal tissue effects from a multicentre, randomised, phase 3, non-inferiority trial. Lancet. 2020;395(10237):1613–1626
Shaitelman SF, Schlembach PJ, Arzu I, et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol 2015; 1:931
26.Bartelink H, Maingon P, Poortmans P, et al. Whole breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16(1):47-56.
Whelan TJ, Olivotto IA, Parpia S, et al. Regional Nodal Irradiation in Early Stage Breast Cancer. N Engl J Med. 2015;373(4):307-316.
Poortmans PM, Collette L, Kirkove C, et al. Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I–III breast cancer: 10-year results of EORTC 22922/10925. N Engl J Med. 2015;373(4):317-327.
Thorsen LB, Offersen BV, Dano H, et al. DBCG-IMN: A population-based randomized clinical trial about the value of internal mammary node irradiation for early node-positive breast cancer. J Clin Oncol. 2016;34(4):314-322.
Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017; 7:4.
Chow R, Hoskin P, Schild SE, et al. Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. Radiother Oncol 2019; 141:56.
Chmura S, Winter KA, Woodward WA, et al.NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol. 2022;40(16S):ASCO #1007.
Jagsi R, Griffith KA, Vicini F, et al. Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort. J Clin Oncol 2020; 38:4019
Jacobson G, Bhatia S, Smith BJ, Button AM.,et al.Randomized trial of pentoxifylline and vitamin E vs standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter.Int J Radiat Oncol Biol Phys. 2013;85(3):604. Epub 2012 Jul 28.
Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S, et al. Prevention and management of acute radiation-induced skin reactions: a systematic review and practice guideline. Support Care Cancer. 2014 Oct;22(10):2931-42.
Taylor C, Correa C, Duane FK, Aznar MC, Anderson S, et al.Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017.
Meric F, Buchholz TA, Mirza NQ, Vlastos G, Ames FC, Ross MI, Pollock RE, Singletary SE, et al.Long-term complications associated with breast-conservation surgery and radiotherapy.Ann Surg Oncol. 2002;9(6):543.
Brunt AM, Haviland JS, Wheatley DA, Sydenham M, Alhasso A, Bloomfield D, Chan C, Churn M, Coles CE, Donovan E, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020 May 23;395(10237):1613-1626
Cordeiro PG, Pusic AL, Disa JJ, McCormick B, Van Zee KJ, Mehrara BJ. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg. 2014 Oct;134(4):644-55.
Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62:1195.
Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65:1.
Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83.
